1
Announcements
Trials
Browse
Landscape
Phase
Phase 1
3
Phase 1/2
1
Status
Completed
4
Sponsor Class
INDUSTRY
3
OTHER
1
Study Type
Interventional
4
Sponsor
Cancer Type
Gastrointestinal
3
Head & Neck
1
Gynecologic
1
Genitourinary
1
Conditions
Colorectal Neoplasms
2
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrent Platinum Resistant Ovarian Cancer
1
Rectal Neoplasms
1
Neoplasm Metastasis
1
Carcinoma
1
Adenoviridae Infections
1
Interventions
Cisplatin
3202
Cyclophosphamide
3195
Carboplatin
2977
Radiotherapy
2790
Paclitaxel
2718
Gemcitabine
2572
pembrolizumab
2385
Bevacizumab
2209
Docetaxel
2199
Fluorouracil
1851
Capecitabine
1833
Oxaliplatin
1742
Dexamethasone
1605
Nivolumab
1581
Doxorubicin
1501
Rituximab
1488
Magnetic Resonance Spectroscopy
1387
Etoposide
1346
Irinotecan
1248
Leucovorin
1226
Drug Therapy
1205
Cytarabine
1130
Pemetrexed
1076
fludarabine
1063
Specimen Handling
1017
Vincristine
964
Cetuximab
945
Trastuzumab
945
Prednisone
942
Lenalidomide
937
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
enadenotucirev
×
Clear all
NCT03916510
2025-02-06
CEDAR
University of Oxford
Phase 1
Completed
12 enrolled
13 charts
NCT02636036
2021-11-09
SPICE
Akamis Bio
Phase 1
Completed
51 enrolled
NCT02028117
2021-05-13
OCTAVE
Akamis Bio
Phase 1
Completed
38 enrolled
NCT02028442
2020-03-12
EVOLVE
Akamis Bio
Phase 1/2
Completed
61 enrolled